Skip to main content

Advertisement

SpringerLink
Log in

Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature

  • Review Article
  • Published:
Updates in Surgery Aims and scope Submit manuscript

Abstract

Patients with unresectable pancreatic ductal adenocarcinoma (UR-PDAC) are traditionally treated with palliative chemotherapy. The aim of this study was to evaluate the safety and efficacy of conversion surgery for initially UR-PDAC following induction therapy. The PubMed and Embase databases were systematically searched for eligible studies published between January 2000 and October 2020. Thirty-two series involving 1270 patients with 1056 locally advanced (LA) disease and 214 distant metastases were reviewed. The median mortality and morbidity was 0% (range 0–10%) and 47.1% (range 8.6–93.3%), respectively. Lymph-node negativity, negative resection margin and pathological complete response were observed in a median of 62.9% (38.5–90.9%), 84.4% (32.8–100%) and 6.7% (0–45.8%) of the specimens. The median survival was 32 (16.4–63.9) months with a 3-year survival rate of 47% (22–80%). Meta-analysis demonstrated that conversion surgery of initially UR-PDAC was associated with a significantly improved survival (hazard ratio [HR] = 0.55; 95% confidence intervals (CI) 0.45–0.66, P < 0.001). There was no significant difference in survival between the group with LA disease and that with distant metastases after conversion surgery (HR = 0.96; 95% CI 0.72–1.28, P = 0.790). Conversion surgery improved long-term survival of patients with initially UR-PDAC who had favorable response to induction therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the united states. Cancer Res 74:2913–2921. https://doi.org/10.1158/0008-5472.Can-14-0155

    Article  CAS  PubMed  Google Scholar 

  2. Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (scalop): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326. https://doi.org/10.1016/s1470-2045(13)70021-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Conroy T, Desseigne F, Ychou M et al (2011) Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. https://doi.org/10.1056/NEJMoa1011923

    Article  CAS  PubMed  Google Scholar 

  4. Marthey L, Sa-Cunha A, Blanc JF et al (2015) Folfirinox for locally advanced pancreatic adenocarcinoma: results of an ageo multicenter prospective observational cohort. Ann Surg Oncol 22:295–301. https://doi.org/10.1245/s10434-014-3898-9

    Article  CAS  PubMed  Google Scholar 

  5. Crippa S, Bittoni A, Sebastiani E et al (2016) Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol 42:1533–1539. https://doi.org/10.1016/j.ejso.2016.06.398

    Article  CAS  PubMed  Google Scholar 

  6. Wright GP, Poruk KE, Zenati MS et al (2016) Primary tumor resection following favorable response to systemic chemotherapy in stage iv pancreatic adenocarcinoma with synchronous metastases: a bi-institutional analysis. J Gastrointest Surg 20:1830–1835. https://doi.org/10.1007/s11605-016-3256-2

    Article  PubMed  Google Scholar 

  7. Bednar F, Zenati MS, Steve J et al (2017) Analysis of predictors of resection and survival in locally advanced stage iii pancreatic cancer: does the nature of chemotherapy regimen influence outcomes? Ann Surg Oncol 24:1406–1413. https://doi.org/10.1245/s10434-016-5707-0

    Article  PubMed  Google Scholar 

  8. Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535

    Article  PubMed  PubMed Central  Google Scholar 

  9. Truty MJ, Kendrick ML, Nagorney DM et al (2021) Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg 273:341–349. https://doi.org/10.1097/sla.0000000000003284

    Article  PubMed  Google Scholar 

  10. Zhu JC, Yan TD, Morris DL (2008) A systematic review of radiofrequency ablation for lung tumors. Ann Surg Oncol 15:1765–1774. https://doi.org/10.1245/s10434-008-9848-7

    Article  PubMed  Google Scholar 

  11. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834. https://doi.org/10.1002/(sici)1097-0258(19981230)17:24%3c2815::aid-sim110%3e3.0.co;2-8

    Article  CAS  PubMed  Google Scholar 

  12. Brunner TB, Grabenbauer GG, Kastl S et al (2000) Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase ii study. Onkologie 23:436–442. https://doi.org/10.1159/000027214

    Article  PubMed  Google Scholar 

  13. Snady H, Bruckner H, Cooperman A et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327. https://doi.org/10.1002/1097-0142(20000715)89:2%3c314::aid-cncr16%3e3.0.co;2-v

    Article  CAS  PubMed  Google Scholar 

  14. Sa Cunha A, Rault A, Laurent C et al (2005) Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg 201:359–365. https://doi.org/10.1016/j.jamcollsurg.2005.04.008

    Article  PubMed  Google Scholar 

  15. Adhoute X, Smith D, Vendrely V et al (2006) Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy. Gastroenterol Clin Biol 30:224–230. https://doi.org/10.1016/s0399-8320(06)73157-8

    Article  PubMed  Google Scholar 

  16. Wilkowski R, Thoma M, Bruns C et al (2006) Chemoradiotherapy with gemcitabine and continuous 5-fu in patients with primary inoperable pancreatic cancer. Jop 7:349–360

    PubMed  Google Scholar 

  17. Lind PA, Isaksson B, Almström M et al (2008) Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma. Acta Oncol 47:413–420. https://doi.org/10.1080/02841860701592384

    Article  CAS  PubMed  Google Scholar 

  18. Bjerregaard JK, Mortensen MB, Jensen HA et al (2009) Long-term results of concurrent radiotherapy and uft in patients with locally advanced pancreatic cancer. Radiother Oncol 92:226–230. https://doi.org/10.1016/j.radonc.2009.04.010

    Article  PubMed  Google Scholar 

  19. Bickenbach KA, Gonen M, Tang LH et al (2012) Downstaging in pancreatic cancer: A matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol 19:1663–1669. https://doi.org/10.1245/s10434-011-2156-7

    Article  CAS  PubMed  Google Scholar 

  20. Satoi S, Yamaue H, Kato K et al (2013) Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the japanese society of hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci 20:590–600. https://doi.org/10.1007/s00534-013-0616-0

    Article  PubMed  Google Scholar 

  21. Kadera BE, Sunjaya DB, Isacoff WH et al (2014) Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg 149:145–153. https://doi.org/10.1001/jamasurg.2013.2690

    Article  PubMed  Google Scholar 

  22. Amano R, Kimura K, Nakata B et al (2015) Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and s-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer. Surgery 158:191–200. https://doi.org/10.1016/j.surg.2015.02.016

    Article  PubMed  Google Scholar 

  23. Hitchcock KE, Nichols RC, Morris CG et al (2017) Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer. World J Gastrointest Surg 9:103–108. https://doi.org/10.4240/wjgs.v9.i4.103

    Article  PubMed  PubMed Central  Google Scholar 

  24. Reni M, Zanon S, Balzano G et al (2017) Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol 28:2786–2792. https://doi.org/10.1093/annonc/mdx495

    Article  CAS  PubMed  Google Scholar 

  25. Sui K, Okabayashi T, Shima Y et al (2017) Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. Br J Radiol 90:20170165. https://doi.org/10.1259/bjr.20170165

    Article  PubMed  PubMed Central  Google Scholar 

  26. Asano T, Hirano S, Nakamura T et al (2018) Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. J Hepatobiliary Pancreat Sci 25:342–350. https://doi.org/10.1002/jhbp.565

    Article  PubMed  Google Scholar 

  27. Ikuta S, Sonoda T, Aihara T et al (2018) The preoperative modified glasgow prognostic score for the prediction of survival after pancreatic cancer resection following non-surgical treatment of an initially unresectable disease. Contemp Oncol (Pozn) 22:229–235. https://doi.org/10.5114/wo.2018.81344

    Article  Google Scholar 

  28. Kluger MD, Rashid MF, Rosario VL et al (2018) Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy. J Gastrointest Surg 22:235–241. https://doi.org/10.1007/s11605-017-3556-1

    Article  PubMed  Google Scholar 

  29. Lee J, Lee JC, Gromski MA et al (2018) Clinical outcomes of folfirinox in locally advanced pancreatic cancer: a single center experience. Medicine (Baltimore) 97:e13592. https://doi.org/10.1097/md.0000000000013592

    Article  CAS  Google Scholar 

  30. van Veldhuisen E, Vogel JA, Klompmaker S et al (2018) Added value of ca19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. HPB (Oxford) 20:605–611. https://doi.org/10.1016/j.hpb.2018.01.001

    Article  Google Scholar 

  31. Byun Y, Han Y, Kang JS et al (2019) Role of surgical resection in the era of folfirinox for advanced pancreatic cancer. J Hepatobiliary Pancreat Sci 26:416–425. https://doi.org/10.1002/jhbp.648

    Article  PubMed  Google Scholar 

  32. Gemenetzis G, Groot VP, Blair AB et al (2019) Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 270:340–347. https://doi.org/10.1097/sla.0000000000002753

    Article  PubMed  Google Scholar 

  33. Maggino L, Malleo G, Marchegiani G et al (2019) Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg 154:932–942. https://doi.org/10.1001/jamasurg.2019.2277

    Article  PubMed  PubMed Central  Google Scholar 

  34. Murphy JE, Wo JY, Ryan DP et al (2019) Total neoadjuvant therapy with folfirinox in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol 5:1020–1027. https://doi.org/10.1001/jamaoncol.2019.0892

    Article  PubMed  PubMed Central  Google Scholar 

  35. Rangelova E, Wefer A, Persson S et al (2021) Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg 273:579–586. https://doi.org/10.1097/SLA.0000000000003301

    Article  PubMed  Google Scholar 

  36. Kato H, Kishiwada M, Hayasaki A et al (2020) Role of serum carcinoma embryonic antigen (cea) level in localized pancreatic adenocarcinoma: cea level before operation is a significant prognostic indicator in patients with locally advanced pancreatic cancer treated with neoadjuvant therapy followed by surgical resection: a retrospective analysis. Ann Surg. https://doi.org/10.1097/sla.0000000000004148

    Article  PubMed  Google Scholar 

  37. Yanagimoto H, Satoi S, Yamamoto T et al (2020) Benefits of conversion surgery after multimodal treatment for unresectable pancreatic ductal adenocarcinoma. Cancers (Basel) 12:1428. https://doi.org/10.3390/cancers12061428

    Article  CAS  Google Scholar 

  38. Klaiber U, Schnaidt ES, Hinz U et al (2021) Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer. Ann Surg 273:154–162. https://doi.org/10.1097/sla.0000000000003270

    Article  PubMed  Google Scholar 

  39. Natsume S, Shimizu Y, Senda Y et al (2019) Conversion surgery only for highly selected patients with unresectable pancreatic cancer: a satisfactory outcome in exchange for a lower resection rate. Surg Today 49:670–677. https://doi.org/10.1007/s00595-019-01776-y

    Article  PubMed  Google Scholar 

  40. Barnes CA, Chavez MI, Tsai S et al (2019) Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery 166:277–285. https://doi.org/10.1016/j.surg.2019.05.010

    Article  PubMed  Google Scholar 

  41. Seufferlein T, Bachet JB, Van Cutsem E et al (2012) Pancreatic adenocarcinoma: Esmo-esdo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii33-40. https://doi.org/10.1093/annonc/mds224

    Article  PubMed  Google Scholar 

  42. Hackert T, Niesen W, Hinz U et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43:358–363. https://doi.org/10.1016/j.ejso.2016.10.023

    Article  CAS  PubMed  Google Scholar 

  43. Kamarajah SK, Bundred JR, Boyle C et al (2020) Impact of neoadjuvant therapy on post-operative pancreatic fistula: a systematic review and meta-analysis. ANZ J Surg 90:2201–2210. https://doi.org/10.1111/ans.15885

    Article  PubMed  Google Scholar 

  44. Awad S, Alkashash AM, Amin M et al (2020) Biochemical predictors of response to neoadjuvant therapy in pancreatic ductal adenocarcinoma. Front Oncol 10:620. https://doi.org/10.3389/fonc.2020.00620

    Article  PubMed  PubMed Central  Google Scholar 

  45. Conroy T, Hammel P, Hebbar M et al (2018) Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379:2395–2406. https://doi.org/10.1056/NEJMoa1809775

    Article  CAS  PubMed  Google Scholar 

  46. Seufferlein T, Hammel P, Delpero JR et al (2019) Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev 77:1–10. https://doi.org/10.1016/j.ctrv.2019.05.007

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Department of Hepatobiliary and Pancreatovascular Surgery, First Hospital of Xiamen University, #55 Zhenhai Road, Xiamen, 361003, China

    Yanming Zhou, Shan Liao, Jun You & Huaxing Wu

Authors
  1. Yanming Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun You
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huaxing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yanming Zhou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Consent is not required for this type of study. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOC 38 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., Liao, S., You, J. et al. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 74, 43–53 (2022). https://doi.org/10.1007/s13304-021-01089-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-021-01089-1

Keyword

Search

Navigation